38151-56-3

Upstream product

• 14578-67-7 4,4-diphenylbutanoic acid 
• 56740-71-7 4,4-diphenyl-1-butanol 
• 36265-55-1 1,1-diphenyl-4-bromobutane 
• 6078-95-1 4,4-diphenyl-3-butenyl bromide 
• 606-83-7 3,3-Diphenylpropionic acid 
• 20017-67-8 3,3-diphenylpropan-1-ol 
• 23426-03-1 3,3-diphenylpropanoic acid methyl ester 
• 41140-53-8 1-Methanesulfonyloxy-3,3-diphenylpropane 
• 22156-48-5 3,3-diphenylpropionitrile 

Downstream Products

• 134420-92-1 ethyl 6,6-diphenyl-2-hexenoate 
• 132287-50-4 2-bromo-4,4-diphenylbutanal 
• 164300-42-9 4-chloromethyl-2-(3,3-diphenyl-propyl)-[1,3]dioxolane 
• 645390-55-2 4,5-bis(chloromethyl)-2-(3,3-diphenylpropyl)-[1,3]dioxolane 
• 169756-85-8 (2S, Z)-1-(tert-Butoxycarbonyl)-4-(4,4-diphenylbutylidene) pyroglutamate ethyl ester 
• 169756-84-7 (2S, E)-1-(tert-Butoxycarbonyl)-4-(4,4-diphenylbutylidene) pyroglutamate ethyl ester 
• 102390-63-6 4⁽⁵⁾-(2,2-Diphenylethyl)imidazole 

Relevant academic research and scientific papers

Metal-Free Enantioselective Oxidative Arylation of Alkenes: Hypervalent-Iodine-Promoted Oxidative C?C Bond Formation

The enantioselective oxyarylation of (E)-6-aryl-1-silyloxylhex-3-ene was achieved using a lactate-based chiral hypervalent iodine(III) reagent in the presence of boron trifluoride diethyl etherate. The silyl ether promotes the oxidative cyclization, and enhances the enantioselectivity. In addition, the corresponding aminoarylation was achieved.

Method of preparing optically active homo-beta-amino acids

The present invention is directed to synthesis of homo-β-amino acids of an optical purity sufficient to exhibit optical activity wherein Curtius rearrangement of 3-mono-substituted succinate acid half ester of an optical purity sufficient to exhibit optical activity is affected and the incipient isocyanate is trapped with a primary or secondary alcohol. The resulting carbamate-protected homo-β-amino esters are then saponified to produce the corresponding carbamate-protected homo-β-amino acids which are deprotected to yield homo-β-amino acids of an optical purity sufficient to exhibit optical activity.

GABA-uptake inhibitors: Construction of a general pharmacophore model and successful prediction of a new representative

A model for the pharmacophore of GABA-uptake inhibitors was established using published structure-activity data and molecular modeling. The model accounted for the activities of different classes of GABA-uptake inhibitors. Analogues of guvacine substituted at position 6 were synthesized in order to confirm the model. 6-(3,3-Diphenylpropyl)guvacine (30f), which fit well with the pharmacophore, had an in vitro IC50 of 0.1 μM. This value is as good as those of the best GABA-uptake inhibitors known today.

Synthesis and structure-activity of 4(5)-(2,2-diphenylethyl)imidazoles as new α2-adrenoreceptor antagonists

4(5)-(2,2-diphenylethyl)imidazole 6a is described as being a potent (pK(i) = 8.16 for displacement of [3H] p-aminoclonidine) and selective (selectivity = -log (pK(i) α2 - pK(i) α1) = 81) α2-adrenoreceptor antagonist (pA2 = 8.73 versus clonidine in the electrically stimulated guinea pig ileum) with additional activity as a norepinephrine uptake inhibitor (IC50 = 0.3 μM). An investigation of the structure-activity relationships of compounds closely related to 6a has been carried out. This included substitution of the phenyl and imidazole rings and modification of the link between these two ring systems. The various synthetic routes used are described. The affinity and the selectivity of the compounds for the α2 site were determined by studying the displacement of [3H] p-aminoclonidine and [3H] WB-4101 from rat forebrain membranes. The efficacy of the compounds was defined by measuring the antagonism of the clonidine effect on the electrically stimulated guinea pig ileum.